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Introduction
Liver has a remarkable ability to replace lost cell mass.
Surgical resection of hepatic lobes triggers hepatocyte rep-
lication. Normally hepatocytes have a quiescent, highly
differentiated phenotype and rarely divide in adult
humans [1,2]. However, their capacity to replicate is read-
ily activated after liver resection or after toxic injury.
A number of studies have demonstrated the involvement
of specific cytokines and growth factors in liver regenera-
tion. The intact liver is relatively unresponsive to exoge-
nous factors but partial hepatectomy provides some
critical element that makes hepatocytes competent to fully
respond to these substances [3,4]. Many growth factors
play important roles in liver regeneration, most notably
hepatocyte growth factor (HGF) and transforming growth
factor a (TGF-alpha) [5,6]. HGF is an important multi-
functional cytokine involved in liver repair after an injury.
It acts as a motogen, a morphogen and a mitogen. Mesen-
chymal cells are responsible for the production of HGF
whereas epithelial cells of various organs and tissues
including the liver normally express HGF receptor cMET.
In the liver HGF is produced by nonparenchymal cells
especially perisinusoidal cells (PC), Kupffer cells (KC) and
endothelial cells (EC). The expression of HGF mRNA dur-
ing liver regeneration is also seen in mesenchymal cells in
the lung and spleen and level of HGF increases in the
blood after partial hepatectomy [7-9]. In contrast to HGF,
which stimulates hepatocyte replication by a paracrine
mechanism, TGF-alpha is an autocrine growth factor that
is produced by hepatocytes and acts on these cells through
binding the epidermal growth factor receptor (EGF-R)
[10]. It is not known whether HGF and TGF-alpha have
identical or complementary functions in hepatocyte
replication.
Human liver regeneration is known to be influenced by
the size of resection and also by the condition of the liver.
Vascular complications and ischemic injury in hepatect-
omized patients could result in adequate regeneration,
leading to hepatic insufficiency [11]. Moreover, regenera-
tion of human liver is influenced by coexisting liver dis-
eases. Clinical experience has shown that resection of
diseased liver sometimes results in postoperative liver fail-
ure due to limited hepatic functional reserve. While con-
siderable interest has been focused on the tumor
recurrence in liver cancer patients who underwent partial
hepatectomy (PH) no data have been reported regarding
the regenerating process after PH in liver tumor-bearing
patients. The growth factors released by cancer cells may
possibly regulate the growth of other cells in paracrine
manner.
The aim of the present study was initiated to determine
the hepatocyte proliferation in relation to the expression
of HGF and TGF-alpha in blood and liver tissue of
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patients with benign and malignant liver tumors after
liver resection.
Methods
Patients
Twenty five consecutive patients undergoing partial hepa-
tectomy for metachronous colorectal carcinoma (MCC)
metastases (15 cases) and benign liver tumors (7 cases of
angioma and 3 cases of cysts) were included in the study.
All liver metastatic patients had currative surgical resec-
tion for primary colorectal carcinoma 4–36 months ear-
lier and received chemotherapy. Informed consent was
obtained from all patients and the trial was approved by
the Medical Research Center Institute and Medical Univer-
sity of Warsaw Ethics Committees.
Blood collection
Blood was collected from all patients before the opera-
tion, 30 min and 7 days after partial hepatectomy. The
serum samples were stored at -20°C until they were used
for HGF and TGF-alpha determination.
Tissue samples
Surgical specimens were collected from: a) resected frag-
ments of liver tissue remote from the tumor; b) tumor tis-
sue; c) remnant liver, 30 min after hepatectomy; d) fine
needle aspiration liver biopsy, 7 days after liver resection.
Tissue samples were fixed in 10% buffered-formalin for
24 h before routine processing in paraffin embedding.
Immunohistochemistry
Immunohistochemical detection of different antigens was
based on avidin-biotin-peroxidase complex technique
(LSAB+Perox rabbit, mouse, goat kit; DAKO, Glostrup).
Monoclonal antibodies to proliferating cell nuclear anti-
gen (PCNA) (NCL-PCNA, Novocastra), HGF (MAB294,
R&D), cMET/HGF-R (NCL-c-MET, Novocastra), TGF-
alpha (AF-239-NA, R&D) and EGF-R (sc-03, Santa Cruz)
were used as primary antibodies. Briefly, sections were
deparaffinized, endogenous peroxidase activity was
blocked with 0.3% hydrogen peroxide in methanol for 30
min. For immunohistochemical detection of HGF, c-MET
and EGF-R slides were immersed in citrate buffer (pH 6.0)
and MV treated. For TGF-a staining, 0.01% protease diges-
tion was performed for 10 min. Before incubation with
primary antibody, the sections were blocked with normal
swine serum, then the primary antibodies were applied
and slides were incubated at 4 degrees C overnight. After
washing, LSABox was applied. Visualization of peroxidase
activity was achieved by mixture of 3.3' – DAB and hydro-
gen peroxide. Slides were counterstained with hematoxy-
lin, mounted and evaluated under the light microscope.
To avoid the relative human error in visual evaluation, we
measured the intensity and the extent of immunostaining
using a computer image analyzer (Micro Image, PC Sony
107, OLYMPUS, Japan) that analyze the image in numer-
ical values.
Quantitative determination of serum HGF and TGF-alpha 
level
Serum HGF and TGF-alpha level was determined with an
enzyme-linked immunoabsorbent assay (ELISA) test kits
(Quantikine; R&D Systems Europe, Ltd., UK (for HGF)
and Oncogene MA, USA (for TGF-alpha) using commer-
cially available reagents according to the manufacture's
instructions. Briefly, serum samples were pipetted into the
wells a microplate precoated with monoclonal antibody
specific for HGF or TGF-alpha. After washing away any
unbound substances, an enzyme-linked polyclonal anti-
body specific for HGF or TGF-alpha was added to the
wells. Following a wash to remove the unbound anti-
body-enzyme reagent, a substrate solution was added to
the wells and the intensity of the color was measured
using a microplate reader (DYNATECH 5000). All meas-
urements were performed in duplicate.
Statistical analysis
Results are expressed as mean values ± SD. The differences
between two samples were defined as significant when P
values by Mann-Whitney U test were less than 0.05.
Results
Clinical data
Fifteen patients with colorectal carcinoma liver metastases
(8 men and 7 women, median age 62.2 ± 7.3 {range 52–
75 years}) and ten patients with benign liver tumors (3
men and 7 women, median age 48.4 ± 4.3 {range 44–59
years}) were investigated. Preoperative liver parenchymal
volume was equivalent in the two groups: malignant
1633.2 ± 560.3 (range 977–1841) cm3; benign 1512.1 ±
419.4 (range 986–2245) cm3. There were no statistically
significant differences in the weight of resected liver tissue
between patients with colorectal carcinoma metastases
and those with benign liver tumors. Although the range of
resected parenchymal weight in malignant and benign
liver tumor patients was wide (462.5 ± 271.5 {range,
120–890} g vs 356.8 ± 217.6 {92–737} g, respectively)
the distribution was comparable between two groups.
Immunohistochemical analysis of PCNA in the liver
PCNA staining was examined in liver tissue sections taken
from the resected organ and remnant liver 30 min and 7
days after hepatectomy. In cells showing positive PCNA
reaction, the nucleus was stained either partially or
entirely reddish brown. The ratio (%) of PCNA positive
nuclei to all nuclei examined was calculated and repre-
sented the PCNA labeling index (PCNA LI) (Fig. 1). Posi-
tive PCNA immunostaining was observed in liver tissue of
60% patients 30 min after hepatectomy and in all patients
7 days after surgery in both groups of patients. PCNA LIComparative Hepatology 2004, 3 http://www.comparative-hepatology.com/content/3/S1/S52
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was significantly higher in liver specimens of benign
lesion patients taken 30 min after liver resection than in
liver tissue before PH (47.1 ± 12.2 vs 0, p < .001). No dif-
ference in the LI was detected between liver tissue taken
from malignant and benign liver tumor patients 30 min
after hepatectomy, however the PCNA LI for colorectal
liver metastatic patients was significantly higher than for
benign tumor group 7 days after liver resection (42.4 ±
10.2 vs 23.0 ± 7.4, p < .05). Interestingly, 9 of 15 patients
with colorectal liver metastases revealed positive PCNA
staining in liver cell nuclei of tissue samples taken from
the resected lobes. In the group of patients with benign
lesions no positive PCNA reaction was found. It was sig-
nificant difference in the LI between malignant and
benign liver tumor patients in liver tissue taken from the
resected lobes (19.2 ± 11.6 vs 0, p < .001).
Serum HGF level
Mean circulating levels of HGF in benign and malignant
liver tumors were within the reference range. There were
no significant differences in the serum HGF level of
benign liver tumor patients between the blood in the pre-
operative period and blood taken 30 min and 7 days after
partial hepatectomy (366.6 ± 127.9 vs 343.9 ± 99.4 vs
422.6 ± 159.9 pg/mL, respectively). Serum levels of HGF
in patients with metachronous colorectal liver metastases
were significantly higher compared with those of patients
with benign liver tumors (618.3 ± 145.2 vs 366.6 ± 127.9
pg/mL, p < .001, before operation; 1045.2 ± 494.0 vs
343.9 ± 99.4 pg/mL, p < .001, 30 min after partial hepate-
ctomy; 750.5 ± 326.1 vs 422.6 ± 159.9 pg/mL, p < .01, 7
days after partial hepatectomy, respectively. In malignant
liver tumor patients serum HGF concentrations were sig-
nificantly increased 30 min after partial hepatectomy
compared with the pre-operative levels and returned to
the pre-operative levels 7 days after operation (1045.2 ±
494.1 vs 618.3 ± 145.2 vs 750.5 ± 326.1 pg/mL, p < .05,
respectively) (Fig. 2).
HGF and c-MET/HGF-R expression in liver specimens
HGF immunostaining was found in 80% (12 of 15) of
liver tissue in colorectal liver metastatic patients and in all
liver specimens taken from benign tumor patients. No dif-
ference in the intensity of HGF expression was detected
between liver samples in malignant and benign tumor
patients taken before and after hepatectomy (Fig. 3).
c-MET/HGF-R expression was found in 80% (12 of 15) of
liver specimens isolated from resected lobes of colorectal
liver metastatic patients and in all liver samples from
benign tumor patients. The intensity of cMET staining in
liver tissue before resection was higher in the benign than
malignant group of patients (0.27 ± 0.02 vs 0.18 ± 0.02, p
< .05). No difference in the expression of c-MET was
observed in liver tissue in both groups during liver
regeneration.
PCNA LI in the liver tissue of patients with metachronous  carcinoma liver metastases (malignant) and benign liver  tumors Figure 1
PCNA LI in the liver tissue of patients with metachronous 
carcinoma liver metastases (malignant) and benign liver 
tumors. Results are presented as the mean percentage of 
positive nuclei ± SD (* p < 0.05, ***p < 0.001).
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Changes in the serum HGF after partial hepatectomy in  patients with metachronous colorectal carcinoma liver  metastases (malignant) and benign liver tumors Figure 2
Changes in the serum HGF after partial hepatectomy in 
patients with metachronous colorectal carcinoma liver 
metastases (malignant) and benign liver tumors. Results are 
expressed as the mean value of pg/mL ± SD (* p < 0.05, ** p 
< 0.01).
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Serum TGF-alpha level
Serum level of TGF-alpha was very low in patients with
malignant (20.1 ± 6.5 pg/mL) and benign (34.2 ± 3.8 pg/
mL) liver tumor. No increase in TGF-alpha level was
found in benign liver tumor patients after partial hepatec-
tomy. Circulating TGF-alpha in peripheral blood of these
patients was almost at the same level: 34.2 ± 3.8 pg/mL
before the operation, 33.7 ± 3.7 pg/mL and 30.4 ± 5.1 pg/
mL 30 min and 7 days after PH, respectively. In patients
with metachronous colorectal carcinoma serum concen-
tration of TGF-alpha was significantly higher 30 min and
7 days after PH than before operation (31.5 ± 6.0 and 29.5
± 6.2 vs 20.1 ± 6.5 pg/mL, p < 0.05, respectively) however,
there was no difference in serum level of TGF-alpha
between malignant and benign liver tumor patients after
PH (Fig. 4).
TGF-alpha and EGF-R/TGF-alpha R expression in liver 
specimens
TGF-alpha expression was detected in 26% (4 of 15) of
liver samples taken from colorectal metastatic patients
before and after hepatectomy. No TGF-alpha staining was
observed in liver specimens taken from the resected lobes
of benign tumor patients however, 20 (2 of 10) and 50%
(5 of 10) liver samples displayed positive
immunoreaction 30 min and 7 days after surgical resec-
tion, respectively. No marked difference in the intensity of
TGF-alpha expression between both groups of patients
during liver regeneration process was found (Fig. 5).
EGF-R was expressed in 86% (13 of 15) of liver specimens
taken from malignant patients before and after
HGF expression in the liver tissue with metachronous color- ectal carcinoma liver metastases (malignant) and benign liver  tumors Figure 3
HGF expression in the liver tissue with metachronous color-
ectal carcinoma liver metastases (malignant) and benign liver 
tumors. Results are expressed as the mean optical density of 
positive immunostaining ± SD.
The level of circulating TGF-alpha in the serum of patients  with metachronous colorectal carcinoma liver metastases  (malignant) and benign tumors after PH Figure 4
The level of circulating TGF-alpha in the serum of patients 
with metachronous colorectal carcinoma liver metastases 
(malignant) and benign tumors after PH. Results are 
expressed as the mean value of pg/mL ± SD.
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TGF-alpha expression in the liver tissue with metachronous 
colorectal carcinoma liver metastases (malignant) and benign 
liver tumors. Results are expressed as the mean optical den-
sity of positive immunostaining ± SD.
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hepatectomy and in all liver samples of benign liver
tumor patients with various intensities. Lower level of
EGF-R immunostaining was observed in liver tissue of
colorectal liver metastatic patients than in patients with
benign lesions before (0.20 ± 0.04 vs 0.29 ± 0.01, p < .05)
and 30 min after liver resection (0.17 ± 0.03 vs 0.27 ±
0.01, p < .01) but no difference in the intensity of EGF-
expression in liver tissue between both groups was found
7 days after hepatectomy.
HGF, c/MET/HGF-R, TGF-alpha and EGF/TGF-alpha R in 
tumor tissue
HGF expression was found in 60% (9 of 15) of adenocar-
cinoma samples and the intensity of staining was similar
to that observed in the liver tissue of malignant tumor
patients. c-Met/HGF-R was detected in 33% (3 of 15) of
tumor specimens. TGF-alpha immunostaining was not
detected in tumor tissues but EGF-R expression was found
in 53% (8 of 15) of tumors.
Discussion
The capacity of the liver to restore major tissue loss within
a few weeks is a unique process involving numerous
interacting cells and a complex network of mediators. This
capacity for liver regeneration is exploited clinically when
partial hepatectomy is used in the treatment of disease.
Clinical experience has shown that recovery after liver
resection is related to the histopathological condition of
the parenchyma, the risk of hepatic failure being higher
when the organ is diseased [12,13]. Extensively studied in
classical animals models, our knowledge of the cellular
process that underlie liver regeneration in humans is
incomplete. Liver regeneration following partial hepatec-
tomy usually does not involve the activation of liver pre-
cursor oval cells. Instead liver mass is replenished by the
proliferation of adult hepatocytes that may replicate in
vivo under natural conditions. The multistep process of
liver regeneration constitutes at least two critical phases:
the transition of the quiescent hepatocytes into cell cycle
(priming) and the progression beyond the restriction
point in the G1 phase of the cycle.
The increase of liver mass most likely was caused by the
rapid induction of hepatocyte proliferation as was shown
by PCNA-positive hepatocytes. The PCNA level is very low
in Go and early G1 phase of cell cycle and increases to a
maximum in the S-phase when it becomes associated with
the DNA replication sites. In our studies the number of
patients showing positive PCNA staining in liver tissue
was higher during regeneration process in both group 30
min and 7 days after liver resection. PCNA LI was signifi-
cantly higher in liver tissue of patients with colorectal
carcinoma liver metastases than in patients with benign
tumor 7 days after partial hepatectomy (PH). Interest-
ingly, PCNA LI in liver tissue taken from the resected lobes
of malignant liver tumor patients was significantly higher
than in liver of benign lesion patients. Normal liver tissue
is negative for PCNA, thus PCNA positive immunostain-
ing observed in liver specimens taken from resected lobes
of metastatic patients argues for stimulation of hepatocyte
proliferation by additional than liver cells' sources.
The correlation between liver cell proliferation and
growth factors levels during liver regeneration in humans
remains unclear. Although multiple factors rise in the
plasma after PH it is likely that one of the key difference
in blood between normal individuals and those subjected
to liver resection is the increased amount of HGF. Hepa-
tocyte growth factor could be produced in many organs or
released from extracellular matrix of the liver [8]. The
serum HGF level alone is not an indicator of liver regener-
ation but it modulates this process since total blood
exchange with normal blood following partial hepatec-
tomy reduces and delays liver regenerative activity in the
early stage [14]. Levels of circulating HGF may vary due to
enhanced production, decreased hepatic clearance or
both because the liver is the major organ through which
HGF is eliminated from the circulation [15]. Serum HGF
level increased in association with hepatocellular
dysfunction, hepatic necrosis and systemic inflammation
[16,17]. In our studies we didn't notice any changes of
HGF level in blood of liver benign tumor patients after PH
however, the increase of serum HGF concentration was
observed in colorectal carcinoma metastatic patients 30
min after liver resection. The amount of circulating HGF
was significantly higher in patients with malignant liver
tumors than in patients with benign lesions. Moreover,
HGF level was higher in preoperative serum of patients
with colorectal carcinoma liver metastases compared with
those with benign tumors. This could be associated with
the presence of adenocarcinoma. Patients with liver
metastases showed slightly higher HGF concentrations in
preoperative serum compared to that without liver metas-
tases [18]. It has been reported previously that HGF is
detected in human cancerous lesions of various organs
[19-22]. In our study, HGF expression was found in color-
ectal liver metastases. This factor could be implicated in
liver cell proliferation. It has been suggested that HGF
plays a bifunctional role in invasive behavior of various
tumors and also in the tissue repair and regeneration in
reaction to tissue damage [23].
HGF is a potent stimulator of DNA synthesis in hepato-
cytes and interacts with other growth factors. Transform-
ing growth factor (TGF-alpha) is another cytokine
involved in hepatic regeneration [24,25]. TGF-alpha is
speculated to interact with HGF in the induction of liver
regeneration following partial hepatectomy, however it is
two to three times less potent than HGF [26]. TGF-alpha
appears to play a role at later times during liverComparative Hepatology 2004, 3 http://www.comparative-hepatology.com/content/3/S1/S52
Page 6 of 7
(page number not for citation purposes)
regeneration. It is induced in hepatocytes within 3 hours
after PH and rises to a peak between 12 and 24 hours [5].
Most if not all types of normal epithelial cells synthesize
TGF-alpha. TGF-alpha can be produced by hepatocytes
themselves thus inducing an autocrine loop. Usually only
a very low level of TGF-alpha is detected in normal liver
but it is higher in regenerating liver [27]. We did not
observed an increase of TGF-alpha expression in liver
samples taken 30 min and 7 days after PH. In our studies
TGF-alpha expression was detected in liver metastases
derived from colorectal carcinoma. Overexpression of
TGF-alpha in liver metastases and primary carcinomas has
been described by others [28]. TGF-alpha has a similar
structure and function to epidermal growth factor (EGF)
thus both TGF-alpha and EGF bind and activate the same
receptor, EGF-R inducing mitogenic and motogenic
response in many cell types. EGF-R expression observed in
hepatocytes of regenerating liver may be involved in cross-
talk between TGF-alpha /EGF-R pathway and the HGF/c-
MET pathway inducing signal amplification as it was pro-
posed by Jo et al [29]. In our studies we did not observe
any difference in the intensity of HGF, TGF-alpha and
their receptors staining in the liver tissue before and after
PH. It might be due to metabolic fate of HGF/c-MET and
TGF-alpha/EGF-R that are rapidly internalized and
degraded as it was shown by in vitro experiments [30].
Therefore, growth factors expression alone is not suffi-
cient to account in relation to liver cell proliferation in
both groups of patients. Further studies at the gene level
are needed. Messenger RNA (m-RNA) and protein levels
in HGF and c-MET expression could be more reliable
markers of liver growth.
In conclusions, our data demonstrated that the prolifera-
tion rate of liver cells was higher in patients with meta-
chronous colorectal liver metastases than in patients with
benign lesions, undergoing partial hepatectomy. It was
correlated with increased level of circulating HGF. Human
liver regeneration is known to be influenced by the size of
resection and also by the condition of the liver. Since the
resected volume of liver tissue was similar in the malig-
nant and benign tumor groups other factors are important
for sustaining proliferation of hepatocytes at higher level
in patients with colorectal liver metastases than in
patients with benign tumors. The mutual interactions
between carcinoma cells and hepatocytes mediated by
carcinoma-derived HGF may play a role in liver regenera-
tion after partial hepatectomy.
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